Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells

References

• Crosbie E, Morrison J. The emerging epidemic of endometrial cancer: time to take action. Cochrane Database Syst Rev 2014;12:ED000095.
   Google Scholar
• Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485–497.
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–1137.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881–887.
   PubMed Web of Science ®Google Scholar
• Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2009;112:150–154.
   PubMed Web of Science ®Google Scholar
• Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol Lett 2015;9:1495–1501.
   PubMed Web of Science ®Google Scholar
• McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004;48(Suppl 1):S7–S12.
   PubMed Web of Science ®Google Scholar
• Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465–2468.
   PubMed Web of Science ®Google Scholar
• Gielen SC, Kuhne LC, Ewing PC, Blok LJ, Burger CW. Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer 2005;12:1037–1049.
   PubMed Web of Science ®Google Scholar
• Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2 is co-expressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998;251:111–116.
   PubMed Web of Science ®Google Scholar
• Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 2003;88:579–585.
   PubMed Web of Science ®Google Scholar
• Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res 2010;12:R32.
   Google Scholar
• Hengel SM, Murray E, Langdon S, Hayward L, O'Donoghue J, Panchaud A, et al. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J Proteome Res 2011;10:4567–4578.
   PubMed Web of Science ®Google Scholar
• Hrstka R, Brychtova V, Fabian P, Vojtesek B, Svoboda M. AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis Markers 2013;35:207–212.
   PubMed Web of Science ®Google Scholar
• Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, Langdon S, et al. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 2010;29:4838–4847.
   PubMed Web of Science ®Google Scholar
• Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker. Breast Cancer Res 2013;15:204.
   PubMed Web of Science ®Google Scholar
• Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 2011;304:1–7.
   PubMed Web of Science ®Google Scholar
• Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005;65:3796–3805.
   PubMed Web of Science ®Google Scholar
• Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008;68:7811–7818.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008;68:492–497.
   PubMed Web of Science ®Google Scholar
• Obacz J, Takacova M, Brychtova V, Dobes P, Pastorekova S, Vojtesek B, et al. The role of AGR2 and AGR3 in cancer: similar but not identical. Eur J Cell Biol 2015;94:139–147.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Satoyoshi R, Aiba N, Kubo T, Yanagihara K, Maeda D, et al. Agr2 mediates paracrine effects on stromal fibroblasts that promote invasion by gastric signet-ring carcinoma cells. Cancer Res 2015;75:356–366.
   PubMed Web of Science ®Google Scholar
• Ostatna V, Vargova V, Hrstka R, Durech M, Vojtesek B, Palecek E. Effect of His6-tagging of anterior gradient 2 protein on its electro-oxidation. Electrochim Acta 2014;150:218–222.
   Web of Science ®Google Scholar
• Tropea JE, Cherry S, Waugh DS. Expression and purification of soluble His(6)-tagged TEV protease. Methods Mol Biol 2009;498:297–307.
   PubMedGoogle Scholar
• Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, et al. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 2008;74:84–87.
   PubMed Web of Science ®Google Scholar
• Hrstka R, Murray E, Brychtova V, Fabian P, Hupp TR, Vojtesek B. Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Lett 2013;333:187–193.
   PubMed Web of Science ®Google Scholar
• Wisniewski JR, Ostasiewicz P, Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 2011;10:3040–3049.
   PubMed Web of Science ®Google Scholar
• Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 2009;8:362–373.
   PubMed Web of Science ®Google Scholar
• Lessey BA, Ilesanmi AO, Castelbaum AJ, Yuan L, Somkuti SG, Chwalisz K, et al. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin. J Steroid Biochem Mol Biol 1996;59:31–39.
   PubMed Web of Science ®Google Scholar
• Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev 2012;6:e15.
   Google Scholar
• Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes JE, et al. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 2010;118:717–725.
   PubMed Web of Science ®Google Scholar
• Chung K, Nishiyama N, Yamano S, Komatsu H, Hanada S, Wei M, et al. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma. Cancer Biomark 2011;10:101–107.
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997–2008.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371–1388.
   PubMed Web of Science ®Google Scholar
• Hrstka R, Bouchalova P, Michalova E, Matoulkova E, Muller P, Coates PJ, et al. AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway. Mol Oncol 2016;10:652–662.
   PubMed Web of Science ®Google Scholar
• Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, et al. Delineation of a FOXA1/ERalpha/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. Mol Cancer Res 2014;12:1829–1839.
   PubMed Web of Science ®Google Scholar
• Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995;136:4996–5003.
   PubMed Web of Science ®Google Scholar
• Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 2000;7:249–256.
   PubMedGoogle Scholar
• Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006–4010.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527–537.
   PubMed Web of Science ®Google Scholar
• Neven P. Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Br J Obstet Gynaecol 1990;97:551–552.
   PubMedGoogle Scholar
• Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol 2005;6:961–971.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005;97:375–384.
   PubMedGoogle Scholar
• Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127–205.
   PubMed Web of Science ®Google Scholar
• Patterson JS, Settatree RS, Adam HK, Kemp JV. Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response. Eur J Cancer 1980;16(Suppl 1):89–92.
   Google Scholar
• Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 2012;14:R91.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu Z, Chen H, Zhu Q, Gao G, Hu L, et al. Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration. Med Oncol 2015;32:577.
   PubMed Web of Science ®Google Scholar
• Andersson H, Helmestam M, Zebrowska A, Olovsson M, Brittebo E. Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos 2010;38:200–207.
   PubMed Web of Science ®Google Scholar
• Higa A, Mulot A, Delom F, Bouchecareilh M, Nguyen DT, Boismenu D, et al. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 2011;286:44855–44868.
   PubMed Web of Science ®Google Scholar
• Chevet E, Fessart D, Delom F, Mulot A, Vojtesek B, Hrstka R, et al. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene 2013;32:2499–2509.
   PubMed Web of Science ®Google Scholar
• Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003;4:117.
   PubMed Web of Science ®Google Scholar
• Maier T, Guell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009;583:3966–3973.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Frackelton Jr. AR, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16:70–84.
   PubMed Web of Science ®Google Scholar
• Skrzypczak M, Schuler S, Lattrich C, Ignatov A, Ortmann O, Treeck O. G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines. Steroids 2013;78:1087–1091.
   PubMed Web of Science ®Google Scholar
• Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004;92:719–725.
   PubMed Web of Science ®Google Scholar